ProPhase Labs, Inc. (PRPH) stock
PRPHOTCPharmaceutical PreparationsFiscal year ends December 31
$0.01−0.00 (-6.16%)
Close on Oct 19, 2026Market cap $119.68KP/E –Yield –
ProPhase Labs r&d expenses
Research and development expenses are spending on new products and technology.
ProPhase Labs's R&D Expenses for the twelve months ending Dec 31, 2025 was $107.00K, down 82.0% year over year. For fiscal 2025 it was $107.00K, down 82.0% from the year before. Over ten years it grew -10.9% a year on average. The highest annual figure on record is $1.40M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $107.00K | -82.0% |
| FY2024 | Dec 31, 2024 | $594.00K | -57.6% |
| FY2023 | Dec 31, 2023 | $1.40M | +115.0% |
| FY2022 | Dec 31, 2022 | $652.00K | +25.4% |
| FY2021 | Dec 31, 2021 | $520.00K | -17.9% |
| FY2020 | Dec 31, 2020 | $633.00K | +90.7% |
| FY2019 | Dec 31, 2019 | $332.00K | -16.6% |
| FY2018 | Dec 31, 2018 | $398.00K | -7.7% |
| FY2017 | Dec 31, 2017 | $431.00K | +20.4% |
| FY2016 | Dec 31, 2016 | $358.00K | +5.3% |
| FY2015 | Dec 31, 2015 | $340.00K | -74.3% |
| FY2014 | Dec 31, 2014 | $1.32M | +60.4% |
| FY2013 | Dec 31, 2013 | $824.00K | -36.7% |
| FY2012 | Dec 31, 2012 | $1.30M | +19.6% |
| FY2011 | Dec 31, 2011 | $1.09M | +37.0% |
| FY2010 | Dec 31, 2010 | $794.00K | -39.3% |
| FY2009 | Dec 31, 2009 | $1.31M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $6.00K | -95.1% |
| Q2 FY2025 | Jun 30, 2025 | $4.00K | -97.1% |
| Q1 FY2025 | Mar 31, 2025 | $97.00K | -64.3% |
| Q4 FY2024 | Dec 31, 2024 | $60.00K | -76.7% |
| Q3 FY2024 | Sep 30, 2024 | $122.00K | -71.5% |
| Q2 FY2024 | Jun 30, 2024 | $140.00K | -75.5% |
| Q1 FY2024 | Mar 31, 2024 | $272.00K | +88.9% |
| Q4 FY2023 | Dec 31, 2023 | $258.00K | -46.0% |
| Q3 FY2023 | Sep 30, 2023 | $428.00K | +289.1% |
| Q2 FY2023 | Jun 30, 2023 | $572.00K | +1942.9% |
| Q1 FY2023 | Mar 31, 2023 | $144.00K | +311.4% |
| Q4 FY2022 | Dec 31, 2022 | $478.00K | +359.6% |
| Q3 FY2022 | Sep 30, 2022 | $110.00K | -47.1% |
| Q2 FY2022 | Jun 30, 2022 | $28.00K | -69.9% |
| Q1 FY2022 | Mar 31, 2022 | $35.00K | -69.6% |
| Q4 FY2021 | Dec 31, 2021 | $104.00K | -77.0% |
| Q3 FY2021 | Sep 30, 2021 | $208.00K | +264.9% |
| Q2 FY2021 | Jun 30, 2021 | $93.00K | +43.1% |
| Q1 FY2021 | Mar 31, 2021 | $115.00K | +94.9% |
| Q4 FY2020 | Dec 31, 2020 | $452.00K | +425.6% |
| Q3 FY2020 | Sep 30, 2020 | $57.00K | 0.0% |
| Q2 FY2020 | Jun 30, 2020 | $65.00K | -31.6% |
| Q1 FY2020 | Mar 31, 2020 | $59.00K | -37.2% |
| Q4 FY2019 | Dec 31, 2019 | $86.00K | +8.9% |
| Q3 FY2019 | Sep 30, 2019 | $57.00K | -60.4% |
| Q2 FY2019 | Jun 30, 2019 | $95.00K | +9.2% |
| Q1 FY2019 | Mar 31, 2019 | $94.00K | +8.0% |
| Q4 FY2018 | Dec 31, 2018 | $79.00K | -30.1% |
| Q3 FY2018 | Sep 30, 2018 | $144.00K | +140.0% |
| Q2 FY2018 | Jun 30, 2018 | $87.00K | -61.2% |
| Q1 FY2018 | Mar 31, 2018 | $87.00K | +155.9% |
| Q4 FY2017 | Dec 31, 2017 | $113.00K | -27.6% |
| Q3 FY2017 | Sep 30, 2017 | $60.00K | +39.5% |
| Q2 FY2017 | Jun 30, 2017 | $224.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $34.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $156.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $43.00K | – |
See a number that looks wrong?